Target
STING (stimulator of interferon genes)
10 abstracts
Abstract
Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.Org: MetroHealth Cancer Center, University of Wisconsin Madison, Cleveland VA,
Abstract
Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.Org: Department of OB/GYN, Duke Cancer Institute of Duke University Health System, CanariaBio, Inc,
Abstract
NeoRad(Low): A phase 2 trial of neoadjuvant (NA) ipilimumab + nivolumab (ipi+nivo) with low dose stereotactic body radiation therapy (SBRT) as an immune stimulant in patients with resectable stage IB-III non-small cell lung cancer (NSCLC).Org: Lifespan Health System, Brown University - Lifespan Cancer Institute, Cancer Center at Brown University, Brown University Department of Family Medicine,
Abstract
Multiplexed trackable intratumor microdosing of the investigational STING agonist TAK-676 alone and in combination in the native tumor microenvironment of patients with head and neck cancer: A phase 0 trial.Org: Presage Biosciences, Inc., Takeda Pharmaceuticals U.S.A., Inc.,
Abstract
Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,
Abstract
Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists.Org: Medical Scientist Training Program, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, Evanston, IL,
Abstract
Enhancing STING activation by cyclic dinucleotide-manganese particles for systemic cancer immunotherapy.Org: University of Michigan, Ann Arbor,
Abstract
Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care, Lombardi Comprehensive Cancer Center, Georgetown University, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK,
Abstract
Doxorubicin to enhance the abscopal effect depending on tumor cell mitochondrial DNA and cGAS/STING.Org: Harbin Medical University Cancer Hospital, West China Hospital, University of Freiburg, Department of Radiation Oncology,
Abstract
A phase I/II trial of NOX66 in combination with nivolumab in patients (pts) with advanced cancer.Org: University of Sydney Medical School, Blacktown Cancer and Haematology Centre, Sydney Adventist Hospital, Western Sydney University, Liverpool Hospital Anatomical Pathology,